One year treatment with exenatide improves β cell function and glycaemic control in metformin treated type 2 diabetes patients

被引：0
|
作者：
Bunck, M. C.
Diamant, M.
Corner, A.
Eliasson, B.
Malloy, J. L.
Shaginian, R. M.
Deng, W.
Kendall, D. M.
Taskinen, M.-R.
Smith, U.
Yki-Jarvinen, H.
Heine, R. J.
机构：
[1] Vrije Univ Amsterdam, Dept Endocrinol, Med Ctr, Amsterdam, Netherlands
[2] Helsinki Univ Hosp, Dept Med, Helsinki, Finland
[3] Sahlgrens Univ Hosp, Lundberg Lab Diabet Res, S-41345 Gothenburg, Sweden
[4] Amylin Pharmaceut Inc, San Diego, CA USA
[5] Eli Lilly & Co, Houten, Netherlands
来源：
DIABETOLOGIA | 2007年 / 50卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0251
引用
收藏
页码：S111 / S112
页数：2
相关论文
共 50 条
  • [31] Exenatide plus metformin and glibenclamide compared with metformin plus glibenclamide on beta cell and alpha cell function and adipocytokines in patients with type 2 diabetes
    Koteshkova, O.
    Antsiferov, M.
    DIABETOLOGIA, 2016, 59 : S378 - S378
  • [32] Effects of exenatide (exendin-4) on glycemic control and weight in patients with Type 2 diabetes treated with metformin and a sulfonylurea
    Kendall, DM
    Riddle, MC
    Zhuang, D
    Kim, DD
    Fineman, MS
    Baron, AD
    DIABETOLOGIA, 2004, 47 : A279 - A280
  • [33] Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients
    Marre, A
    Van Gaal, L
    Usadel, KH
    Ball, A
    Whatmough, I
    Guitard, C
    DIABETES OBESITY & METABOLISM, 2002, 4 (03): : 177 - 186
  • [34] Exenatide achieved equivalent glycaemic control to insulin glargine, with weight reduction and less nocturnal hypoglycaemia, in metformin and sulfonylurea-treated type 2 diabetes
    Heine, RJ
    Van Gaal, LF
    Johns, D
    Mihm, MJ
    Widel, MH
    Brodows, RG
    DIABETOLOGIA, 2005, 48 : A3 - A3
  • [35] Exenatide plus metformin compared to metformin alone on beta cell function in type 2 diabetic patients
    Maffioli, P.
    Franzetti, I. G.
    Querci, F.
    Carbone, A.
    Ciccarelli, L.
    Piccinni, M.
    Fogari, E.
    Ferraro, M. A.
    Derosa, G.
    DIABETOLOGIA, 2012, 55 : S298 - S298
  • [36] Extended, 3-year, exenatide therapy shows sustainable effects on beta cell disposition index in metformin treated patients with type 2 diabetes
    Bunck, M. C.
    Corner, A.
    Eliasson, B.
    Heine, R. J.
    Shaginian, R. M.
    Taskinen, M. -R.
    Smith, U.
    Yki-Jarvinen, H.
    Diamant, M.
    DIABETOLOGIA, 2010, 53
  • [37] Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin
    Riddle, Matthew C.
    Henry, Robert R.
    Poon, Terri H.
    Zhang, Bei
    Mac, Susanna M.
    Holcombe, John H.
    Kim, Dennis D.
    Maggs, David G.
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2006, 22 (06) : 483 - 491
  • [38] The Effects of Exenatide and Metformin on Endothelial Function in Newly Diagnosed Type 2 Diabetes Mellitus Patients: A Case–Control Study
    Yanjin Hu
    Jia Liu
    Guang Wang
    Yuan Xu
    Diabetes Therapy, 2018, 9 : 1295 - 1305
  • [39] EXENATIDE VERSUS INSULIN GLARGINE IN TYPE 2 DIABETES INADEQUATELY TREATED WITH METFORMIN
    Polyzos, S. A.
    Zografou, I.
    Karagianni, P.
    Kartali, N. I. K. I.
    Sampanis, C.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2015, 17 : A50 - A50
  • [40] Glycaemic control and adverse events in patients with type 2 diabetes treated with metformin plus sulphonylurea: a meta-analysis
    Belsey, J.
    Krishnarajah, G.
    DIABETES OBESITY & METABOLISM, 2008, 10 : 1 - 7
12345